According to a recent LinkedIn post from All G, the company has been awarded $1.1 million from the New South Wales Government’s Biosciences Fund to support development of human milk proteins in Australia. The post indicates that the funding will be directed toward advancing work on human beta-casein.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests the capital will help move its technology from laboratory development toward proof-of-concept scale-up, regulatory readiness and eventual manufacturing. For investors, this could signal meaningful de-risking of All G’s precision fermentation platform and may enhance its positioning in emerging alternative dairy and infant nutrition markets.
As highlighted in the post, backing from the Office of the NSW Chief Scientist & Engineer and the NSW Government points to growing public-sector support for biotechnology innovation in the region. This type of non-dilutive funding may improve All G’s runway, support further R&D, and potentially make the company a more attractive partner or acquisition target within the global food-tech and biosciences ecosystem.